GO:0046898 response to cycloheximide explained

GO:0046898 response to cycloheximide is a biological process Gene Ontology term defined as any process that results in a change in state or activity of a cell or an organism as a result of a cycloheximide stimulus. Cycloheximide (actidione) is an antibiotic produced by some Streptomyces species that interferes with protein synthesis in eukaryotes [QuickGO definition]. Because it rapidly blocks translation elongation, cycloheximide has become a standard tool for distinguishing immediate signaling events from responses that require newly synthesized proteins [1,3]. In pituitary perifusion systems, cycloheximide altered the response to continuously superfused gonadotropin-releasing hormone, indicating that protein synthesis is required for sustained gonadotropin release. Similarly, the transcriptional response of the human chorionic gonadotropin beta-subunit gene to cAMP was cycloheximide sensitive, while the alpha-subunit response was not, showing gene-specific dependence on new protein synthesis. Beyond its use as a translation inhibitor, cycloheximide itself can elicit stress and apoptotic responses. In Tetrahymena pyriformis, cycloheximide exposure produced stress-protein changes that differed from arsenite and heat shock, defining a distinct stress signature. In toxicological studies, cycloheximide-induced apoptosis followed a biphasic dose response, a common pattern in cell death regulation. More recently, cycloheximide-resistant ribosomes in C. elegans revealed adaptive translation dynamics, demonstrating that cells can remodel their translational machinery in response to cycloheximide. These findings make GO:0046898 a useful framework for studying translational control, stress signaling, and hormone-dependent gene expression.

In plain terms, GO:0046898 response to cycloheximide covers everything a cell or organism does after encountering cycloheximide. The QuickGO definition states that it is any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cycloheximide stimulus. Cycloheximide is an antibiotic from Streptomyces that interferes with protein synthesis in eukaryotes. The term therefore includes direct consequences of translation inhibition, such as loss of short-lived proteins, as well as secondary stress, transcriptional, secretory, and apoptotic responses triggered by the drug [1,2,3,4,5].

GO:0046898 is important because cycloheximide is one of the most widely used experimental tools for dissecting whether a biological response depends on new protein synthesis. In neuroendocrine research, cycloheximide sensitivity distinguished sustained gonadotropin release from rapid secretion and revealed gene-specific requirements for cAMP-induced hCG beta-subunit transcription. In stress biology, cycloheximide itself acts as a stressor, producing distinct stress-protein profiles in Tetrahymena and biphasic apoptotic dose responses. In translational biology, cycloheximide-resistant ribosomes in C. elegans show that cells can adapt their translation machinery under drug pressure. Understanding this term therefore supports studies of hormone signaling, apoptosis, stress adaptation, and ribosome function, with implications for cancer, neurodegeneration, and ribosomopathies.

The following genes and proteins are experimentally linked to response to cycloheximide through studies of translation, hormone signaling, stress, and apoptosis.

Response to cycloheximide is regulated at multiple levels. The primary trigger is direct inhibition of eukaryotic protein synthesis by cycloheximide [QuickGO definition]. Downstream, gene-specific transcriptional sensitivity depends on cis-acting sequences and on whether a response requires newly synthesized proteins, as shown for the hCG beta-subunit gene. Stress-responsive pathways can be activated, producing stress-protein changes distinct from other stressors. Apoptotic regulation follows biphasic dose-response behavior, meaning the magnitude and direction of the response depend on cycloheximide concentration. Finally, adaptive changes in ribosome composition or function can reduce sensitivity, as seen with cycloheximide-resistant ribosomes in C. elegans.

Cycloheximide-induced apoptosis follows biphasic dose responses, a pattern relevant to understanding how cancer cells respond to translation inhibition and death signals. Because many tumors depend on high protein synthesis rates, genes controlling response to cycloheximide may inform therapeutic strategies that target translation [2,5].

Cycloheximide sensitivity of gonadotropin release and hCG beta-subunit transcription links GO:0046898 to reproductive neuroendocrinology [1,3]. Perturbations in these pathways are relevant to disorders of gonadotropin regulation and fertility [1,3].

Cycloheximide-resistant ribosomes in C. elegans demonstrate that ribosome composition can adapt under drug pressure. This connects response to cycloheximide to ribosomopathies and diseases in which translation stress contributes to pathology.

Cycloheximide elicits stress-protein responses distinct from arsenite and heat shock in Tetrahymena. Such stress signatures are relevant to understanding cellular responses in inflammatory and stress-related diseases.

Ribosome profiling measures translation genome-wide and can reveal how cycloheximide alters ribosome occupancy. It is especially useful for studying adaptive translation dynamics and cycloheximide-resistant ribosomes.

RNA-seq can identify genes whose transcriptional responses to cAMP or other stimuli are cycloheximide sensitive, as shown for the hCG beta-subunit gene. Comparing treated and untreated samples distinguishes direct from indirect transcriptional effects.

Protein-level methods can detect stress-protein changes induced by cycloheximide and compare them with other stressors such as arsenite or heat shock. These approaches define the stress signature of response to cycloheximide.

Apoptosis assays across a range of cycloheximide concentrations can reveal biphasic dose responses. Such experiments are essential for interpreting cell death outcomes in cancer and toxicology studies.

Researchers studying response to cycloheximide-related genes often need to determine whether a candidate gene is causally involved in translation inhibition, stress signaling, or apoptosis. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses directly.

GO:0046898 response to cycloheximide captures the diverse cellular and organismal changes triggered by a classic translation inhibitor. From hormone secretion and gene-specific transcription to stress-protein induction, biphasic apoptosis, and adaptive ribosome changes, the term connects fundamental translation biology to disease-relevant processes [1,2,3,4,5]. CRISPR-based models and modern profiling methods now make it possible to test causal genes and mechanisms with precision, supporting research in cancer, neuroendocrinology, and ribosomopathies [2,3,5].